Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™: INTENSIFY ALL)

NCT01059812 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01059812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01059812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™: INTENSIFY ALL)
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
February 1, 2010
Completion date
December 23, 2010
Enrollment
424 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2